Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669572 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
A Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06669572 is a Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 35 participants, below the 258-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06669572, a Phase 2 study of Carcinoma, Squamous Cell and Anorectal Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2029-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06669572
The ClinicalTrials.gov registry entry for NCT06669572 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 258-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (86% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Squamous Cell appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06669572 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06669572 about?
NCT06669572 is a clinical study titled "Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment". The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
What is the current status of trial NCT06669572?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-07-11. Estimated completion is 2029-03-26.
What conditions does trial NCT06669572 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Anorectal Cancer.
What interventions are being tested in trial NCT06669572?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT06669572?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06669572 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Squamous Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
ACTIVE NOT RECRUITING · Phase 2
-
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
COMPLETED · Phase 2
-
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.